Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Eli Lilly 22.974, AstraZeneca 15.384.
Eli Lilly vs AstraZeneca Net Worth and Market Cap
Eli Lilly (LLY) and AstraZeneca (AZN) are peers in GLP-1. Eli Lilly reported revenue of $23.0B as of Q2 2026, compared with $15.4B for AstraZeneca. Eli Lilly leads on revenue.
Eli Lilly's gross margin is 85.8% versus 83.6% for AstraZeneca. Eli Lilly's net margin is 30.9% versus 16.3% for AstraZeneca.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: Eli Lilly +47.7%, AstraZeneca +6.4%.
- Eli Lilly keeps more of its revenue as operating profit: a 54.2% operating margin, against 20.6% at AstraZeneca.
- Eli Lilly's KPIs on Sterling include Cardiometabolic Manufacturing Capex Announcements by Site (Cumulative) and Foundayo Quarterly Revenue.
- AstraZeneca's KPIs on Sterling include Alliance Revenue by Partnered Medicine (Quarterly) and AZD5004 + AZD6234 Trial Timeline: Oral GLP-1 + Oral Amylin.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Eli Lilly, AstraZeneca.| Metric | Eli Lilly | AstraZeneca |
|---|---|---|
| Market Cap | - | - |
| Revenue | $22.97B | $15.38B |
| Cost of Revenue | $3.27B | $2.52B |
| Gross Profit | $19.71B | $12.86B |
| Operating Income | $12.46B | $3.16B |
| Net Income | $7.09B | $2.51B |
| R&D Expense | $3.82B | $4.05B |
| Earnings Per Share | $7.94 | $1.59 |
| Gross Margin | 85.8% | 83.6% |
| Operating Margin | 54.2% | 20.6% |
| Net Profit Margin | 30.9% | 16.3% |
| Free Cash Flow | $7.76B | $2.13B |
| Cumulative Free Cash Flow | $109.66B | $121.22B |
| Operating Cash Flow | $10.69B | $2.89B |
| Cash & Equivalents | $8.89B | $4.89B |